Status:
RECRUITING
Heparin vs Placebo for Cardiac Catheterization
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions:
Cardiac Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Patients undergoing cardiac catheterization will be randomized to 3 groups: no anticoagulant, low dose anticoagulant and high dose anticoagulant.
Detailed Description
Patients undergoing diagnostic cardiac catheterization via the trans-radial approach will be randomly allocated (1:1:1) to receive either low-dose UFH (25 IU/Kg -maximal dose 3,000 IU), high-dose UFH ...
Eligibility Criteria
Inclusion
- diagnostic cardiac catheterization; Small size sheath; patency of the ulno-palmar circulation
Exclusion
- abnormal ulno-palmar circulation; Prior radial artery thrombosis; Prior surgery close to the access site; Emergent cardiac catheterization; History of HIT or allergy to heparin; Patients requiring anticoagulation
Key Trial Info
Start Date :
October 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
3600 Patients enrolled
Trial Details
Trial ID
NCT04374799
Start Date
October 5 2020
End Date
December 1 2026
Last Update
August 24 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamilton Health Sciences
Hamilton, Ontario, Canada
2
London Health Sciences Centre
London, Ontario, Canada, N6A5A5